Neurogene Inc. Capitalized Computer Software, Amortization
Neurogene Inc. (NGNE) reported Capitalized Computer Software, Amortization of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedComputerSoftwareAmortization1 · last filed 2026-03-24
- Neurogene Inc. capitalized computer software, amortization for fiscal 2025 was $100.00K, a 75.00% decline from fiscal 2024.
- Neurogene Inc. capitalized computer software, amortization for fiscal 2024 was $400.00K, a 100.00% increase from fiscal 2023.
- Neurogene Inc. capitalized computer software, amortization for fiscal 2023 was $200.00K, a 0.00% change from fiscal 2022.
- Neurogene Inc. capitalized computer software, amortization for fiscal 2022 was $200.00K.
| Period end | Capitalized Computer Software, Amortization 12 month |
|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $400.00K 10-K · filed 2026-03-24 |
| 2023-12-31 | $200.00K 10-K · filed 2025-03-24 |
| 2022-12-31 | $200.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |